Related Experiment Video
Updated: Jul 19, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Christopher J Schulze1, Kyle J Seamon1, Yulei Zhao2
1Department of Biology, Revolution Medicines, Inc., Redwood City, CA 94063, USA.
Abstract:
The discovery of small-molecule inhibitors requires suitable binding pockets on protein surfaces. Proteins that lack this feature are considered undruggable and require innovative strategies for therapeutic targeting. KRAS is the most frequently activated oncogene in cancer, and the active state of mutant KRAS is such a recalcitrant target. We designed a natural product-inspired small molecule that remodels the surface of cyclophilin A (CYPA) to create a neomorphic interface with high affinity and selectivity for the active state of KRASG12C (in which glycine-12 is mutated to cysteine). The resulting CYPA:drug:KRASG12C tricomplex inactivated oncogenic signaling and led to tumor regressions in multiple human cancer models. This inhibitory strategy can be used to target additional KRAS mutants and other undruggable cancer drivers. Tricomplex inhibitors that selectively target active KRASG12C or multiple RAS mutants are in clinical trials now (NCT05462717 and NCT05379985).
Related Concept Videos
Export of Misfolded Proteins out of the ER
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Molecular Chaperones and Protein Folding
The...
Bacterial Protein Maturation
Targeted Cancer Therapies
There are several types of targeted therapies against...

